A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Mantle Cell Lymphoma (MCL)
BIOLOGICAL: Lisocabtagene maraleucel
Adverse events (AEs), Up to 15 years
Complete remission rate (CRR), Up to 15 years|Overall response rate (ORR), Up to 15 years|Progression-free survival (PFS), Up to 15 years|Overall survival (OS), Up to 15 years
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).